Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Matthew R. Smith,Shahneen Sandhu,William Kevin Kelly,Howard I. Scher,Eleni Efstathiou,Primo N. Lara,Evan Y. Yu,Daniel J. George,Kim N. Chi,Jason Summa,Nishi Kothari,Xin Zhao,Byron M. Espina,Deborah Ricci,Jason S. Simon,Namphuong Tran,Karim Fizazi

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

2019

Matthew R. Smith
Shahneen Sandhu
William Kevin Kelly
Howard I. Scher
Eleni Efstathiou
Primo N. Lara
Evan Y. Yu
Daniel J. George
Kim N. Chi
Jason Summa
Nishi Kothari
Xin Zhao
Byron M. Espina
Deborah Ricci
Jason S. Simon
Namphuong Tran
Karim Fizazi

202Background: New therapies are needed for patients (pts) with mCRPC progressing after androgen-receptor signaling inhibitors (ARSIs) and taxane therapies. Niraparib is a once daily highly selecti...

Keywords:

Phases of clinical research
Prostate cancer
DNA repair
Castration
Pathology
Oncology
Medicine
Internal medicine
once daily
castration resistant
in patient
Taxane

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations